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Mitochondria likely play a role in Parkinson’s disease (PD) neurodegeneration. We modelled PD by creating cytoplasmic hybrid
(cybrid) cell lines in which endogenous mitochondrial DNA (mtDNA) from PD or control subject platelets was expressed within human
teratocarcinoma (NT2) cells previously depleted of endogenous mtDNA. Complex I activity was reduced in both PD cybrid lines and in
the platelet mitochondria used to generate them. Under basal conditions PD cybrids had less ATP, more LDH release, depolarized
mitochondria, less mitochondrial cytochrome c, and higher caspase 3 activity. Equivalent MPP+ exposures are more likely to trigger
programmed cell death in PD cybrid cells than in control cybrid cells. Our data support a relatively upstream role for mitochondrial
dysfunction in idiopathic PD.
 2008 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
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Parkinson’s disease (PD) is the second most common
neurodegenerative disorder. It is characterized by extensive
loss of nigrostriatal dopaminergic neurons. Residual nigral
neurons contain intraneuronal inclusions called Lewy
bodies (LBs). Five to 10% of cases are postulated to have
a genetic component, while the majority is categorized as
idiopathic and sporadic. Sporadic PD prevalence is age-
associated, with approximately 1% of the population
aﬀected at 65 years and 4–5% at 85 years of age (Reviewed
in Cardoso et al., 2005).1567-7249/$ - see front matter  2008 Elsevier B.V. and Mitochondria Resear
doi:10.1016/j.mito.2008.03.004
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239 820190; fax: +351 239 822776.
E-mail address: smacardoso@yahoo.com (S.M. Cardoso).
1 These authors contributes equally to this work.While the etiology of the disease for most aﬀected people
remains unclear, mitochondrial dysfunction likely plays a
key role in PD pathogenesis. Mitochondria are central
not only to cell bioenergetics but also to apoptotic cell
death (Shults, 2004). They are believed to play a fundamen-
tal role in ageing, and interact with speciﬁc proteins previ-
ously implicated in genetic forms of this neurodegenerative
disease.
Several lines of evidence link sporadic PD to mitochon-
drial dysfunction. Complex I activity is reduced in both
autopsy brain and platelets of sporadic PD subjects (Parker
et al., 1989; Shapira et al., 1989, 1990; Mizuno et al., 1989).
Recently, Keeney and co-workers observed complex I is
oxidatively damaged in PD brain (Keeney et al., 2006).
While the mechanisms underlying this are not entirely
clear, in sporadic PD mutated or oxidatively damaged
mitochondrial DNA (mtDNA) may play a contributory
role (Ibeke et al., 1995; Cortopassi and Wang, 1995).ch Society. All rights reserved.
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at least in part from mtDNA (Swerdlow et al., 1996, 1998;
Gu et al., 1998; Shults and Miller, 1998). Interestingly, rel-
ative to other brain areas the substantia nigra contains par-
ticularly high levels of large mtDNA deletions (Soong
et al., 1992). These mtDNA deletions likely cause func-
tional impairment in aged human substantia nigra neurons
(Kraytsberg et al., 2006). PD brains also have discrete
microheteroplasmic mutations in the ND5 gene that distin-
guish them from control brains (Smigrodzki et al., 2004;
Parker and Parks 2005). Together, these studies suggest
mtDNA may mediate mitochondrial dysfunction in PD
and therefore contribute to PD neurodegeneration.
To address the relevance of mitochondrial function to
PD, we used a cytoplasmic hybrid (cybrid) approach to
generate a disease-speciﬁc, ex-vivo model of mitochondrial
dysfunction. This approach has previously been used to
produce cell culture models of PD mitochondrial dysfunc-
tion; successful studies utilizing SH-SY5Y and A549
human cell line nuclear backgrounds are reported (Swerd-
low et al., 1996, 1998; Gu et al., 1998; Shults and Miller,
1998). This technique involves the transfer of platelet mito-
chondria from either PD or control subjects to mtDNA-
depleted recipient cells (rho0 cells). The resulting cybrid
lines express the nuclear genes of the recipient rho0 cell line
and the mitochondrial genes of the platelet donor. If mito-
chondrial defects found in transferred platelet mitochon-
dria persist in culture, it is hypothesized mtDNA should
account for those persistent defects. Regardless of the role
of mtDNA, though, cybrid models facilitate the study of
downstream consequences of mitochondrial dysfunction
in PD (Swerdlow et al., 1996; Ghosh et al., 1999).
We now report for the ﬁrst time an analysis of PD
cybrids prepared using a human teratocarcinoma (NT2)
nuclear background. We further used these cell lines to
study how PD and control (CT) cybrid cell lines respond
to a mitochondrial toxin, 1-methyl-4-phenylpyridinium
ion (MPP+). MPP+, a metabolite of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), induces Parkinsonism
in humans, primates, and mice (Langston et al., 1983;
Beal, 2001). It causes anatomically speciﬁc degeneration
of substantia nigra pars compacta and locus coeruleus
catecholaminergic neurons by inhibiting complex I of
the mitochondrial respiratory chain (Przedborski et al.,
2004; Mochizuki et al., 1996). In addition to ﬁnding
the complex I defect of PD platelets perpetuates in
NT2 PD cybrids, we describe for the ﬁrst time that
MPP+ treated CT cybrids showed mitochondrial impair-
ments similar to untreated PD cybrids. Furthermore,
mitochondrial dysfunction observed in untreated PD
cybrids renders them more susceptible to MPP+ induced
mitochondrial dependent apoptosis.
2. Materials and methods
Subject participation was approved by the Institutional
Review Board of the University Hospital of Coimbra.PD subjects were recruited from the Neurology Service at
the University Hospital of Coimbra and met the Gelb
and co-workers (1999) criteria for probable PD. They did
not manifest signs or symptoms of an alternative neurode-
generative disease. The mean age of the CT group (n = 3)
was 64.3 ± 8.4, and for the PD group (n = 2) was 65.0 ± 5.
2.1. Preparation of platelet mitochondria
Following informed consent, 60 ml of blood was col-
lected through venipuncture in tubes containing acid–cit-
rate–dextrose as an anticoagulant. Mitochondria were
obtained from human platelets according to previously
described methods (Krige et al., 1992). Platelet mitochon-
dria protein concentrations were measured by the Bradford
protein assay (Bradford, 1976), in which bovine serum
albumin was used as the standard.
2.2. Cell culture
These experiments utilized NT2 human teratocarcinoma
cells (Stratagene, La Jolla, CA) depleted of endogenous
mtDNA (rho0 cells) via long-term ethidium bromide expo-
sure (Swerdlow et al., 1997; Binder et al., 2005). Platelet
mitochondria from either PD or CT subjects were used
to repopulate NT2 rho0 cells with mtDNA as previously
described (Swerdlow et al., 1997; Binder et al., 2005).
Untransformed cells were removed by withdrawal of pyru-
vate and uridine from the culture medium and substitution
of dialyzed, heat inactivated fetal calf serum for non-dia-
lyzed, heat inactivated fetal calf serum (Swerdlow et al.,
1996; Miller et al., 1996). Speciﬁcally, the selection medium
consisted of Optimen (Gibco Life Technologies) supple-
mented with 10% dialyzed, heat inactivated fetal calf
serum, penicillin (50 U/mL), and streptomycin (50 lg/
mL). Cells were grown in 75 cm2 tissue culture ﬂasks main-
tained in a humidiﬁed incubator at 37 C and 5% CO2.
For the MTT assay, cells were plated in 24-well plates at
a density of 0.1  106 cells/well. For rhodamine 123 mea-
surements, cells were plated in 24-well plates at a density
of 0.05  106 cells/well. For ATP and LDH determina-
tions, cells were plated in 12-well plates at a density of
0.2  106 cells/well. For measurements of caspase enzyme
activities, Western blot analysis of a-spectrin, and Western
blot analysis of poly (ADP-ribose) polymerase (PARP)
cells were plated in 6-well plates at a density of
0.5  106 cells/well. For Western blot analysis of cyto-
chrome c and determinations of electron transport chain
(ETC) enzyme activities, cells were plated in petri dishes
(10 cm) at a density of 2.5  106 cells/dish.
2.3. MPP+ treatment
MPP+ was purchased from Sigma. Twenty-four hours
after plating, cybrid cell lines were treated with 100, 500
or 1 mM MPP+ (water diluted) and maintained at 37 C
for another 24 h. For each experimental parameter, a con-
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MPP+.2.4. Electron microscopy
Cell suspensions were ﬁxed with 3% glutaraldehyde in
0.1 M phosphate-buﬀered pH 7.3 overnight at 4 C. The
ﬁxed pellets were washed in 0.1 M phosphate-buﬀered. Pel-
lets were then post-ﬁxed with 1% osmium tetroxide during
2 h, dehydrated in grade ethanol and embedded in Spurr.
The ultrathin sections were cut with an LKB ultra-micro-
tome ULTRATOME III, and then contrasted with uranyl
acetate and with lead citrate for transmission electron
microscopy. Electron microphotographs were taken with
JEOL JEM-100 SX electron microscope operated at 80 kV.2.5. Mitochondrial respiratory chain complexes
2.5.1. NADH-ubiquinone oxidoreductase assay
Complex I activity was determined by a modiﬁed ver-
sion of Ragan et al. (1987), which follows the decrease in
NADH absorbance at 340 nm that occurs when ubiqui-
none (CoQ1) is reduced to form ubiquinol. The reaction
was initiated by adding CoQ1 (50 lM) to the 30 C reac-
tion mixture. After 5 min, rotenone (10 lM) was added
and the reaction was followed for another 5 min. Complex
I activity was expressed both as nanomoles per minute per
milligram of protein, as well as the ratio of complex I activ-
ity per citrate synthase activity.2.5.2. Succinate-cytochrome c oxidoreductase assay
Complex II/III activity was measured by following the
formation of reduced cytochrome c at 550 nm (King,
1967). The sample was pre-incubated at 30 C for 5 min
with 20 mM succinate and 1 mM KCN prior to addition
of the cytochrome c. The assay was performed at 30 C.
Activity of complex II/III was expressed both as nano-
moles per minute per milligram of protein, as well as the
ratio of complex II/III activity per citrate synthase activity.2.5.3. Cytochrome c oxidase assay
Complex IV activity was determined using the method
of Wharton and Tzagotoﬀ (1967), which measures the oxi-
dation of reduced cytochrome c by cytochrome c oxidase at
550 nm. To prepare reduced cytochrome c, cytochrome c
was mixed with a few crystals of ascorbate and partitioned
by a dialysis membrane overnight against 0.01 M phos-
phate buﬀer, pH 7.0 at 4 C. The reduced cytochrome c
concentration was then determined using 0.1 M potassium
ferricyanide. The reaction mixture contained 0.01 M potas-
sium phosphate, pH 7.0, and 50 lM reduced cytochrome c.
The reaction was initiated by addition of the sample at
30 C. The pseudo ﬁrst order rate constant (K) was calcu-
lated, because the reaction is of ﬁrst order with respect to
cytochrome c. Results are expressed both as K per minute
per milligram of protein, as well as the quotient of the cyto-chrome oxidase activity divided by the citrate synthase
activity.
2.6. Citrate synthase assay
Citrate synthase activity was determined by the method
of Coore et al. (1971), which spectrophotometrically fol-
lows the formation of 5-thio-2-nitrobenzoate at 412 nm.
The assay was initiated by the addition of 100 lM oxaloac-
etate at 30 C. Results were obtained in nanomoles per
minute per milligram of protein.
2.7. Analysis of adenine nucleotides
After the 24 h cell plating-incubation period, medium
was removed. Cells were extracted, on ice, with 0.4 M per-
chloric acid. Cells were next centrifuged at 14,000 rpm for
5 min at 4 C. The resulting pellets were solubilized with
1 M NaOH to further analyse protein content by the Brad-
ford method. The resulting supernatants were neutralized
with 5 M KOH and 2.5 M Tris, pH 7–8, and then centri-
fuged at 14,000 rpm for 5 min at 4 C. These supernatants
were assayed for adenine nucleotides (ATP, ADP and
AMP) by reversed-phase HPLC as described by Stocchi
et al. (1985). The chromatographic apparatus used was a
Beckam Gold System, consisting of a 126 Binary Pump
Model and a 166 Variable UV detector that was controlled
by computer. The column was a Lichrospher 100 RP-18
(5 lm) from Merk (Germany). An isocratic elution with
100 mM KH2PO4 buﬀer at pH 7.4 and 1% methanol was
performed at a ﬂow rate of 1.2 ml/min. The adenine nucle-
otides were detected at 254 nm for 6 min.
2.8. Cell viability assays
2.8.1. MTT reduction
Cell viability was determined by the colorimetric MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay (Mosmann, 1983). In viable cells, the enzyme
succinate dehydrogenase metabolizes MTT into a forma-
zan that absorbs light at 570 nm. Following the cell treat-
ment protocol the medium was aspirated and 0.5 ml
MTT (0.5 mg/ml) was added to each well. The plate was
then incubated at 37 C for 3 h. At the end of the incuba-
tion period the formazan precipitates were solubilized with
0.5 ml of acidic isopropanol (0.04 M HCl/Isopropanol).
The absorbance was measured at 570 nm. Cell reduction
ability was expressed as a percentage of the CT cybrids.
2.8.2. Lactate dehydrogenase release
In order to quantify the degree of plasma membrane
injury, we determined the activity of the cytoplasmic
enzyme lactate dehydrogenase (LDH) in the extracellular
incubation medium. LDH activity was measured spectro-
photometrically according to the method of Bergmeyer
and Brent (1974), which follows the conversion of NADH
to NAD+ at 340 nm. LDH release was expressed as a per-
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activity measured in the supernatant plus the activity mea-
sured after incubating the cells in a 15 mM Tris solution,
pH 7.4.
2.9. Mitochondrial dependent apoptosis
2.9.1. Analysis of mitochondrial membrane potential (Dwm)
2.9.1.1. Rhodamine 123 probe. Rhodamine 123, a ﬂuores-
cent cationic dye, was used to monitor changes in mito-
chondrial membrane potential. Plated cells were washed
with phosphate-buﬀered saline (PBS) and incubated with
1 lM rhodamine 123 for 45 min at 37 C. Basal ﬂuores-
cence was read using excitation and emission wavelengths
of 505 and 525 nm, respectively. Next, 1 mg/ml oligomycin
and 6 lM FCCP were added and the plate was read at
37 C. Rhodamine 123 retention capacity was calculated
as the diﬀerence between the ﬁnal ﬂuorescence (after oligo-
mycin and FCCP exposure) and the initial ﬂuorescence.
Results are expressed as a percentage of the dye retained
within the untreated CT cybrids.
2.9.1.2. MitoTracker Red probe. MitoTracker Red was
used to assess mitochondrial membrane potential. Cells
were grown on coverslips in 12-well plates. After treatment,
cells were washed twice with PBS and incubated with
500 nm MitoTracker Red for 45 min at 37 C. Cells were
then washed twice with PBS and ﬁxed for 30 min at room
temperature in 4% paraformaldehyde. The ﬁxed cells were
washed again with PBS, and observed under a confocal
microscope.
2.9.2. Western blot analysis of mitochondrial cytochrome c
Following MPP+ treatment cells were washed with PBS,
scraped in a buﬀer containing 250 mM sucrose, 20 mM
Hepes, 1 mM EDTA, 1 mM EGTA, and protease inhibi-
tors (0.1 M phenyl-methylsulfonyl ﬂuoride (PMSF),
0.2 M dithiothreitol (DTT), and 1:1000 dilution of a prote-
ase inhibitor cocktail) and homogenized. Cells were frozen
three times on liquid nitrogen and the lysate was centri-
fuged at 2200 rpm for 12 min at 4 C. The resulting super-
natant was centrifuged at 9600 rpm for 10 min at 4 C.
Pellets resulting from this step constitute a crude mitochon-
drial fraction. The amount of protein was measured by the
Bradford method and 25 lg of protein from each condition
was loaded per well. The samples were resolved by electro-
phoresis in 12% SDS–polyacrylamide gels and transferred
to PVDF membranes. Non-speciﬁc binding was blocked
by gently agitating the membranes in 5% non-fat milk
and 0.1% Tween in TBS for 1 h at room temperature.
The blots were subsequently incubated with the respective
primary antibodies [mouse puriﬁed anti-Cytochrome C
(denatured) [(1:500) (BD Pharmingen)]] overnight at 4 C
with gentle agitation. Blots were washed with TBS contain-
ing 0.1% non-fat milk and 0.1% Tween three times (each
time for 15 min), and then incubated with the secondary
antibodies [anti-mouse (1:20000)] for 2 h at room tempera-ture with gentle agitation. After three washes speciﬁc bands
of interest were detected by developing with ECF detection
reagent (Amersham). Fluorescence signals were detected
using a Biorad Versa-Doc Imager.
2.9.3. Caspase activation assays
Caspase activation was measured using a colorimetric
method described by Cregan et al. (1999), in which the sub-
strate cleavage is monitored at 405 nm. After treatment
with MPP+, cells were washed and placed in buﬀer contain-
ing 25 mM HEPES, 1 mM EDTA, 1 mM EGTA, 2 mM
MgCl2, and protease inhibitors (0.1 M PMSF, 2 mM
DTT, and a 1:1000 dilution of a protease inhibitor cock-
tail). Cells were harvested by scraping and frozen three
times on liquid nitrogen. The lysate was centrifuged for
10 min at 14,000, 4 C. The resulting supernatant was
stored at 80 C. Protein concentrations were measured
by the Bradford method. Lysates (50 lg of protein) were
incubated at 37 C for 2 h in 25 mM HEPES, pH 7.5 con-
taining 0.1% CHAPS, 10% sucrose, 2 mM DTT, and
40 lM Ac-LEHD-pNA or 40 lM Ac-DEVD-pNA (Cal-
biochem) to determine caspase 9 or caspase 3 activation,
respectively.
2.9.4. PARP and a-spectrin cleavage
Following experimental treatments, cells were scraped in
a buﬀer containing 25 mM HEPES, 1 mM EDTA, 1 mM
EGTA, 2 mM MgCl2, and protease inhibitors (0.1 M
PMSF, 0.2 M DTT, and 1:1000 dilution of a protease
inhibitor cocktail). Cells were then frozen three times on
liquid nitrogen and stored at 80 C. The amount of pro-
tein was measured by the Bradford protein assay. Equal
amounts of protein samples (50 lg per condition) were ﬁrst
resolved by electrophoresis in 10% (for PARP) or 7% (for
a-spectrin) SDS–polyacrylamide gels. The electrophoresed
proteins were transferred to PVDF membranes. Non-spe-
ciﬁc binding was blocked by gently agitating the blots in
5% non-fat milk and 0.1% Tween in TBS for 1 h at room
temperature. The blots were subsequently incubated with
the respective primary antibodies [mouse anti a-spectrin
monoclonal antibody [(1:1000) (Chemicon)]] and mouse
anti-PARP [(1:2000) (Cell Signaling)]] overnight at 4 C
with gentle agitation. All the blots were washed with TBS
containing 0.1% non-fat milk and 0.1% Tween three times
(each time for 15 min), and then incubated with the second-
ary antibodies [anti-mouse (1:20000)] for 2 h at room tem-
perature with gentle agitation. After three washes speciﬁc
bands of interest were detected following development with
the ECF detection reagent. Fluorescence was detected
using a Biorad Versa-Doc Imager.
2.10. Data analysis
Data provided are the mean ± SE. At least three inde-
pendent measurements were made for each experiment.
Statistical analyses were conducted using one-way
ANOVA. Post hoc Bonferroni testing was also performed.
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p < 0.05.3. Results
3.1. Ultrastructure of mitochondria in cybrids
At the ultrastructural level, CT cybrids had a eukaryotic
nucleus, and dark, oval mitochondria (Fig. 1A). However,
PD cybrids contained pale and enlarged shaped mitochon-
dria with disrupted cristae (Fig. 1A).3.2. Mitochondrial function in platelets and cybrids
We measured citrate synthase (CS) activities to ensure
similar degrees of mitochondrial enrichment occurred
between compared groups. PD and CT platelet CS activi-
ties were equivalent, as were PD and CT cybrid CS activi-
ties (Data not shown).
The results of our CS-corrected mitochondrial respira-
tory chain (MRC) complex activities are shown in Table
1. After correcting for CS activity, complex I activity was
lower in PD platelet mitochondria than it was in CT plate-
let mitochondria. For NT2 cybrids prepared using mito-
chondria from the same platelet donors, a reduction inFig. 1. (A) Electron microscopy of a PD and a CT cybrid cell. CT cybrid have
matrix. PD cybrids have also a euchromatic nucleus (N) and oval mitochondr
disrupted cristae (arrowhead) (8000). (B) ATP levels in PD and CT cybrid
Mean ± SEM ATP levels for each group were calculated from duplicate determ
a percentage of each group mean ATP level as compared to the mean ATP l
diﬀerent as compared to the untreated CT cybrid group.
Table 1
Activity of mitochondrial respiratory chain complexes in PD platelet mitocho
CT platelet mitochondria PD platelet mi
Complex I/CS 2.35 ± 0.48 1.23 ± 0.34*
Complex II/III/CS 2.27 ± 0 64 1.46 ± 1.18
Complex IV/CS 0.42 ± 0.15 0.37 ± 0.01
* P < 0.05, signiﬁcantly diﬀerent as compared to CT platelet mitochondria.
** P < 0.01, signiﬁcantly diﬀerent as compared to CT cybrids.the PD group complex I/CS activity was again observed.
Additionally, complex IV/CS activity was lower in PD
cybrids than it was in control cybrids.
We also assessed the eﬀects of MPP+ on PD and CT
cybrid MRC enzyme activities. Both groups showed equiv-
alent degrees of complex I and IV inhibition (Table 2).
We measured ATP levels in PD and CT cybrids at base-
line and following 1 mMMPP+ exposure. Basal ATP levels
were lower in PD cybrids, but following MPP+ exposure
CT and PD ATP levels were equivalent. MPP+ caused a
signiﬁcant reduction in CT but not PD cybrid ATP levels
(Fig. 1B).3.3. MPP+ toxicity in PD and CT cybrids
The ability of cells to reduce MTT is often used as a via-
bility screen. Under basal conditions PD cybrids tended
towards less MTT reduction than CT cybrids, but this
parameter did not reach statistical signiﬁcance (Fig. 2A).
When exposed to varying concentrations of MPP+ for
24 h, both PD and CT cybrids exhibited a dose-dependent,
roughly equivalent decrease in MTT reduction capacity.
Cell viability was also assessed using an LDH release
assay (Fig. 2B). Under basal conditions PD cybrids
released more LDH than CT cybrids. Although MPP+a euchromatic nucleus (N) and rod-shaped mitochondria (M) with a dark
ia (M) with pale matrix. PD cybrids mitochondria are enlarged and with
s. Cell ATP levels were determined by HPLC as described in Section 2.
inations from four diﬀerent experiments. In the ﬁgure, data are reported as
evel of the untreated CT cybrid group. *p < 0.05; **p < 0.01, signiﬁcantly
ndria and PD cybrids
tochondria CT cybrids PD cybrids
0.63 ± 0.02 0.31 ± 0.07**
0.06 ± 0.04 0.05 ± 0.02
1,24x10’5 ± 0.08x10’5 0,55x10’5 ± 0.12x10-5**
Table 2
Mitochondrial respiratory chain complexes in MPP+ treated cybrids
CT cybrids MPP+/CT cybrids PD cybrids MPP+/PD cybrids
Complex I (nmol/min/mg) 16.58 ± 2.86 9.53 ± 0.09** 11.65 ± 1.46** 9.38 ± 0.81**
Complex II/III (nmol/min/mg) 1.52 ± 0.58 LIS ± 0.31 2.09 ± 0.55 1.83 ± 0.57
Complex IV (nmol/min/mg) 0.39 ± 0.11 0.14 ± 0.04* 0.23 ± 0.14* 0.07 ± 0.02*
* P < 0.05, signiﬁcantly diﬀerent as compared to CT platelet mitochondria.
** P < 0.01, signiﬁcantly diﬀerent as compared to CT cybrids.
Fig. 2. Eﬀects of MPP+ on MTT reduction and LDH release. Cybrid cells
were incubated in the presence of 100, 500, 1000 lM MPP+. (A) The
ability of cells to reduce MTT was determined as described in Section 2.
Data are expressed as a percentage of the untreated CT cybrid group, with
the mean ± SEM from ﬁve independent experiments. *p < 0.05; **p < 0.01,
signiﬁcantly diﬀerent from the untreated CT cybrid group; #p < 0.05,
signiﬁcantly diﬀerent from the untreated PD cybrid group. (B) The eﬀect
of MPP+ on membrane integrity was evaluated by LDH quantiﬁcation, as
described in Section 2. Data are expressed as the mean ± SEM values
from ﬁve independent experiments. *p < 0.05; ***p < 0.001, signiﬁcantly
diﬀerent as compared to the untreated CT cybrid group; ##p < 0.01,
signiﬁcantly diﬀerent as compared to the untreated PD cybrid group.
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tude of the MPP+-induced LDH release increase was
greater in the CT cybrid group. Despite this, at the higher
MPP+ concentrations the amount of LDH released by CTcybrids was still less than the amount released from PD
cybrids.3.4. Activation state of the intrinsic apoptosis pathway
The amount of rhodamine 123 taken up and retained by
mitochondria is proportional to the magnitude of the mito-
chondrial membrane potential. Under basal conditions
rhodamine 123 levels were lower in PD cybrids than in
CT cybrids. This indicates the mitochondrial membrane
potential was reduced in PD cybrids (Fig. 3A). Experi-
ments performed with MitoTracker Red were consistent
with those using rhodamine 123, in that under basal condi-
tions the PD cybrid mitochondrial membrane potential was
reduced relative to that of CT cybrids (Fig. 3B). Both
approaches showed 1 mM MPP+ exposure depolarised
mitochondria in CT cybrids, but did not appreciably
reduce PD cybrid mitochondrial membrane potentials.
Following MPP+ exposure, mitochondrial membrane
potentials were similar between cybrid groups.
Mitochondrial fractions prepared from PD cybrids con-
tained less cytochrome c than mitochondrial fractions pre-
pared from CT cybrids (Fig. 3C). One millimolar of MPP+
exposure reduced mitochondrial cytochrome c levels in
both PD and CT cybrid cell lines. Levels of mitochondrial
cytochrome c were decreased in MPP+-treated PD cybrids
as compared to CT cybrids.
Under basal conditions, caspase 9 activities were equiv-
alent between PD and CT cybrids (Fig. 4A). MPP+ acti-
vated caspase 9 only at the highest dose studied (1 mM
MPP+), and even then only for the PD cybrids. Caspase
3 activity was higher in PD cybrids under basal conditions,
but not with 100 or 500 uM MPP+ exposures (Fig. 4B).
Neither of these MPP+ concentrations was associated with
increased caspase 3 activity in either PD or control cybrids.
At the 1 mM MPP+ concentration caspase 3 activity was
increased in both PD and CT cybrids. At this MPP+ con-
centration, caspase 3 activities were comparable between
the PD and CT cybrid groups.
To further evaluate caspase 3 status, we immunochemi-
cally assessed PARP and alpha spectrin cleavage in PD and
CT cybrids before and after MPP+ treatment. Caspase 3-
mediated cleavage of a-spectrin yields 120 and 150 kDa
fragments. As demonstrated in Fig. 5A, under basal condi-
tions levels of both of these fragments were increased in PD
cybrids. One millimolar of MPP+ induced a-spectrin cleav-
age in both PD and CT cybrid lines, and following MPP+
Fig. 3. Mitochondrial membrane potential and cytochrome c content. (A) Mitochondrial membrane potential was expressed as the percentage of
rhodamine 123 retention in untreated CT cybrids, with the mean ± SEM derived from ﬁve independent experiments. *p < 0.05, **p < 0.01, signiﬁcantly
diﬀerent as compared to CT untreated cybrids. (B) Mitochondrial membrane potential was also analysed using MitoTracker Red. Three independent
experiments were performed for each cell line. The ﬁgure shows actual results from a representative experiment. (C) Basal mitochondrial cytochrome c
levels were reduced in PD cybrids. Each cybrid cell line was assayed three times. The ﬁgure shows actual Western blot results from a representative
experiment.
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of a-spectrin cleavage products. PARP, a 116 kDa protein,
is cleaved by caspase 3 to an N-terminally truncated
89 kDa derivative. Under basal conditions minimal PARP
cleavage was observed in either PD or CT cybrids. MPP+
increased PARP cleavage in both cybrid groups
(Fig. 5B). As was the case with our a-spectrin analysis,
there was a trend towards greater activation (under both
basal and MPP+-treatment conditions) of caspase 3 in
PD cybrids.
4. Discussion
Our data conﬁrm prior studies showing complex I activ-
ity is reduced in PD subject platelets (Schapira and Mars-den, 1994; Barroso et al., 1993; Parker et al., 1989;
Yoshino et al., 1992; Benecke et al., 1993; Haas et al.,
1995; Blandini et al., 1998). Our data further conﬁrm and
extend prior studies demonstrating mitochondrial transfer
from PD subject platelets to rho0 cells produces cybrid cell
lines in which complex I Vmax activities are reduced relative
to cybrid cell lines containing mitochondria from control
subjects (Swerdlow et al., 1996; Cassarino et al., 1997).
Complex I activity is reduced in PD brain (Shapira et al.,
1989, 1990; Gu et al., 1998; Janetzky et al., 1994). It seems
reasonable to postulate a common underlying factor causes
complex I activity reductions in both these tissues. The fact
that complex I dysfunction perpetuates in PD cybrids sug-
gests mtDNA may account for systemic alteration of com-
plex I in this disease.
Fig. 4. Caspase 9-like and caspase 3-like activity in PD and CT cybrids. Cells were incubated in 0, 100, 500, or 1000 lMMPP+ over 24 h. Caspase activity
was measured spectrophotometrically at 405 nm, as described in Section 2. (A) Caspase 9 activation was determined by Ac-LEHD-pNA cleavage. (B)
Caspase 3 activation was determined by Ac-DEVD-pNA cleavage. Data represent mean ± SEM values derived from six independent determinations.
#p < 0.05, ##p < 0.01, signiﬁcantly diﬀerent as compared to PD untreated cybrids; *p < 0.05, **p < 0.01, signiﬁcantly diﬀerent as compared to CT untreated
cybrids.
226 A. R. F. Esteves et al. /Mitochondrion 8 (2008) 219–228MPP+ had a greater eﬀect on CT cybrid than it did on
PD cybrid MTT reduction capacity, LDH leakage, ATP
levels, and mitochondrial membrane potential. Some of
these endpoints were perturbed in PD cybrids even without
MPP+ exposure, and these perturbations may have limited
the amount of further change MPP+ could induce. It is
interesting to note that in general, MPP+ caused CT
cybrids and their mitochondria to resemble PD cybrids
and their mitochondria. If mitochondrial function is truly
relevant to PD pathogenesis, then these ﬁndings could help
explain why MPTP causes Parkinsonism.
An intrinsic apoptotic cascade is associated with mito-
chondrial depolarisation, mitochondrial cytochrome c
release, and caspase 9 activation. Our mitochondrial cyto-
chrome c content, and caspase 9 activity data further sug-
gest that when exposed to a mitochondrial toxin such as
MPP+, PD mitochondria are more likely than healthy
mitochondria to activate the intrinsic apoptotic cascade.
Our data extend the ﬁnding of Swerdlow and collabora-
tors, showing that SH-SY5Y PD cybrids treated with
MPP+ had a trend towards greater staining of apoptotic
nuclei (Swerdlow et al., 1996). Substantial data from others
argue environmental factors contribute to PD, conceivably
by interfering with mitochondrial function. Persons with
mitochondrial proﬁles similar to those observed in this
study may be particularly susceptible to environmentally
encountered mitochondrial toxins.Data presented in this paper show evidences that allow
us to propose a new unifying hypothesis for late onset, spo-
radic PD. Swerdlow and Khan previously proposed the
‘‘mitochondrial cascade hypothesis” for sporadic Alzhei-
mer’s disease (AD), which postulates an upstream role
for mitochondrial dysfunction in AD neurodegeneration
(Swerdlow and Khan, 2004). This hypothesis is largely sup-
ported by data from cybrid models, as such models are pro-
duced through expression of mitochondrial genes from a
non-degenerating tissue and therefore are unlikely to sim-
ply represent an artefact of tissue degradation. Based on
data from this and prior studies of PD cybrids, we feel it
is possible mitochondrial dysfunction in PD may represent
a relatively upstream pathology and that a ‘‘mitochondrial
cascade” paradigm may also apply in late-onset, sporadic
PD as well.
Under our PD mitochondrial cascade hypothesis
schema, inherited polymorphic mtDNA variation is postu-
lated to inﬂuence age-related declines in mitochondrial
function. This age-related mitochondrial dysfunction may
itself arise through accumulation of somatic mtDNA
mutations that decrease an individual’s mitochondrial
ETC eﬃciency from an inherited set point. When a partic-
ular threshold of mitochondrial dysfunction is reached
within the substantia nigra, neurodegeneration and PD-
associated histopathologic changes result. In support of
this view, Manfredi (2006) recently summarized data sug-
Fig. 5. Caspase 3 substrate cleavage. (A) Caspase 3-mediated a-spectrin
cleavage before and after 1000 lM MPP+ is shown. The Western blot in
the ﬁgure represents results of an actual experiment. Each cybrid cell line
was analysed three independent times. (B) Caspase 3-mediated PARP
cleavage before and after 1000 lM MPP+ is shown. The Western blot in
the ﬁgure represents results of an actual experiment. Each cybrid cell line
was analysed three independent times.
A. R. F. Esteves et al. /Mitochondrion 8 (2008) 219–228 227gesting dopaminergic neurons of the substantia nigra accu-
mulate high levels of mtDNA deletions. The extent of these
deletions is arguably beyond the threshold required to
cause respiratory chain mitochondrial dysfunction (Manf-
redi, 2006).
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